Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Register now for the “Q4 Earnings Season Wrap-Up.”
Join stock market expert Marc Chaikin (the creator of Chaikin Money Flow) and Explosive Options’ Bob Lang for a special earnings season wrap-up.

You’ll find out the biggest takeaways from recent earnings results and what it means for the market—and YOUR money. 

Menu

Summit Therapeu ADR (SMMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,992
  • Shares Outstanding, K 13,844
  • Annual Sales, $ 33,080 K
  • Annual Income, $ -9,280 K
  • 36-Month Beta 1.19
  • Price/Sales 0.30
  • Price/Cash Flow N/A
  • Price/Book 0.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/19
See More
  • Average Estimate -0.39
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.45
  • Prior Year -1.15
  • Growth Rate Est. (year over year) +66.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.21 +7.44%
on 02/15/19
1.66 -21.69%
on 02/01/19
-0.12 (-8.45%)
since 01/18/19
3-Month
1.10 +18.18%
on 01/02/19
1.67 -22.16%
on 01/08/19
-0.03 (-2.26%)
since 11/20/18
52-Week
1.10 +18.18%
on 01/02/19
14.29 -90.90%
on 04/20/18
-10.12 (-88.62%)
since 02/20/18

Most Recent Stories

More News
New Research Coverage Highlights Global Payments, Tableau Software, Summit Therapeutics, Utah Medical Products, Apollo Commercial Real Estate Finance, and Urstadt Biddle Properties -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Global Payments Inc. (NYSE:GPN),...

UTMD : 90.80 (unch)
GPN : 125.94 (+1.26%)
DATA : 127.04 (+0.06%)
UBA : 21.71 (-0.69%)
SMMT : 1.30 (unch)
ARI : 18.05 (+0.39%)
Antimicrobials Working Group Announces Updates to Leadership Team

The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr....

MLNT : 1.33 (+7.26%)
ITRM : 5.78 (-0.60%)
CFRX : 0.46 (-4.17%)
MTFB : 1.95 (-11.36%)
SMMT : 1.30 (unch)
SCYX : 1.41 (+2.17%)
CDTX : 2.55 (+0.79%)
NBRV : 2.06 (+0.49%)
PRTK : 7.14 (-1.11%)
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply

Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.

SRPT : 140.57 (+0.22%)
MYGN : 31.98 (+1.59%)
SMMT : 1.30 (unch)
EDIT : 20.55 (+1.63%)
New Strong Sell Stocks for December 19th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

JOUT : 65.63 (-0.56%)
VST : 26.64 (+0.19%)
SMMT : 1.30 (unch)
HPR : 2.79 (+2.95%)
SGPYY : 34.9300 (-0.03%)
Detailed Research: Economic Perspectives on OUTFRONT Media, Limoneira, Papa John's International, Everi, Premier, and Summit Therapeutics -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OUTFRONT Media Inc. (NYSE:OUT),...

PZZA : 43.49 (+0.42%)
LMNR : 23.25 (+0.96%)
SMMT : 1.30 (unch)
EVRI : 7.74 (+1.57%)
PINC : 38.07 (-0.05%)
OUT : 21.41 (-0.14%)
New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc....

ESPR : 43.88 (+0.78%)
CMVLF : 16.4400 (+2.62%)
SMMT : 1.30 (unch)
RPD : 45.41 (-1.30%)
OCN : 2.11 (-12.45%)
FRAC : 11.45 (+3.25%)
CLLS : 17.18 (-4.13%)
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

ARQL : 3.31 (+2.16%)
SMMT : 1.30 (unch)
PFE : 42.20 (-0.94%)
MKGAF : 111.3500 (+1.46%)
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018

Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic candidates for the treatment of gonorrhoea in a late-breaking presentation at the 28th...

SMMT : 1.30 (unch)
Award of Share Options and Restricted Stock Units

Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), announces that the following options over new ordinary shares of one penny nominal value ('Ordinary Shares') were granted on 20 April 2018 to the Chief...

SMMT : 1.30 (unch)
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial

Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces the completion of ezutromid dosing in patients with Duchenne muscular dystrophy ('DMD') for the full 48-week PhaseOut DMD clinical trial. Top-line...

SMMT : 1.30 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SMMT with:

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

2nd Resistance Point 1.41
1st Resistance Point 1.35
Last Price 1.30
1st Support Level 1.27
2nd Support Level 1.25

See More

52-Week High 14.29
Fibonacci 61.8% 9.25
Fibonacci 50% 7.70
Fibonacci 38.2% 6.14
Last Price 1.30
52-Week Low 1.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar